US White House Proposes Pre-Market Review for AI: 'Certified' Like Drugs Before Launch

Hot Hook

Imagine: before an AI chatbot can go live, it must pass a review similar to the FDA's drug approval—fail and it never sees the light of day. This isn't science fiction, but a new regulation being brewing by the US White House. According to reports, the White House wants to establish a "pre-market review" mechanism to conduct safety assessments for high-risk AI systems, similar to the approval process for drugs and medical devices. This move targets the pain point of AI's "wild growth": Is the AI you use really safe?

Core Facts

According to multiple media reports including The Street, the White House is considering pre-market review for AI. Key changes include:

• Timing: Recent policy discussions, not yet formal legislation;
• Agency: Led by the White House Executive Office, possibly involving the National Institute of Standards and Technology (NIST) and others;
• Key Change: AI classified by risk level; high-risk applications (e.g., medical diagnosis, autonomous driving, law enforcement decisions) must submit safety test reports, bias audits, explainability documentation, etc., before commercial use.
• Background: The previous Trump administration signed an AI executive order emphasizing military AI protects Americans' rights; this review leans more toward "preventive regulation" of civilian AI.

Breakdown for Laypeople

Analogy: It's like buying cold medicine at a pharmacy—it must have a "National Drug Approval Number" to be sold. The White House wants to apply this logic to AI: any AI tool aimed at the public must first prove it is "harmless," such as not leaking privacy arbitrarily, not being racist, not suddenly going crazy and giving wrong advice.

Currently, AI is mostly "launch first, fix later" (like software patches), but some AI accidents (e.g., autonomous driving hitting people, algorithmic discrimination in loans) have severe consequences. A review mechanism would require vendors to pre-simulate risks, make training data transparent, and undergo third-party testing.

Impact by Group

• Workplace employees: If using AI for decision-making (e.g., resume screening, financial analysis), review may bring more reliable tools, but some high-risk AI may be temporarily suspended, affecting efficiency. Suggestion: monitor company compliance, retain human review processes.
• Students: Academic AI tools (e.g., essay assistants) may be restricted to prevent cheating. But more transparent review reduces risks of "toxic textbooks." Note: don't rely entirely on unreviewed AI for assignments; self-discipline is safer.
• Creators: AI-generated works (copywriting, illustrations) used commercially may require copyright source declarations to avoid infringement. Beneficial for open-source and compliant platforms; when taking orders, prefer tools with "safety certification."
• General users: The most direct beneficiaries—error rates for facial recognition payments, smart customer service, and medical diagnosis may decrease. But caution: review may push up AI costs, some free services may become paid or shrink.

Comparison Table:

Group	Benefit	Risk	Follow the Trend?
Workplace employees	Safer & easier to use	Short-term tool limitations	Wait and see, prepare alternatives
Students	Reduce reliance on errors	Some tools banned	Return to basic skills
Creators	Enhanced copyright protection	Review costs passed on	Choose certified platforms
General users	Increased privacy rights	Service price increases	Choose rationally, don't blindly follow

Pros/Cons + Pitfalls

Advantages:

1. Prevent problems before they occur: Avoid large-scale correction after AI errors, such as misidentification in facial recognition, credit discrimination.
2. Enhance credibility: Users trust "vetted" AI more, promoting long-term industry health.
3. Force transparency: Vendors must disclose training data and algorithm logic, reducing black-box operations.

Disadvantages/Challenges:

1. Slow innovation: Review cycles are long (like drug approval takes years), small companies may not afford the cost, favoring big tech monopolies.
2. Hard to set standards: What is "safe"? Who defines it? Could be politicized or become "formalism" of simple registration.
3. Global fragmentation: If US standards differ from EU and China, cross-border AI services will split, users forced to adapt multiple versions.

Pitfall Avoidance Guide:

• Beware of vendors who claim "no review needed, so we're good" — they may be deliberately bypassing regulation;
• Don't easily give sensitive data (e.g., medical records, face scans) to AI without review explanation;
• When investing in AI stocks, consider if the company has compliance reserves (e.g., audit teams); short-term may be impacted by policy.

A Touch of Humanism

Technology is never a "frictionless" progress. Drug regulation may cause some wonder drugs to be delayed, but it has saved countless people from fake drug poisonings. AI review is similar; it's not a question of "whether or not," but of "how to balance elegantly." Every moment of caution toward technology is actually a respect for human fragility. We don't need to glorify "speed of updates" nor demonize "the hand of regulation." Remember: true wisdom is finding your own pace between running and tying your shoelaces.

Engage with Us

Do you think AI "pre-market review" will kill innovation or protect users? If an AI tool you use is suddenly taken down for review, would you support or oppose it? Feel free to share your experiences and opinions in the comments.